Alumis Inc
ALMS4.720USD
0.000
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
491.08MValor de mercado
PerdaP/L TTM
Mais detalhes de Alumis Inc Empresa
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Informações de Alumis Inc
Código da empresaALMS
Nome da EmpresaAlumis Inc
Data de listagemJun 28, 2024
CEOMr. Martin Babler
Número de funcionários168
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 28
Endereço280 East Grand Avenue
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone16502316625
Sitehttps://www.alumis.com/
Código da empresaALMS
Data de listagemJun 28, 2024
CEOMr. Martin Babler
Executivos da empresa Alumis Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Detalhamento da receita
FY2025Q2
FY2025Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.67M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Ayur Maya Capital Management Company, L.P.
15.63%
Foresite Capital Management, LLC
10.35%
Samsara BioCapital, LLC
4.96%
VenBio Partners LLC
4.77%
The Vanguard Group, Inc.
4.16%
Outro
60.14%
Investidores
Investidores
Proporção
Ayur Maya Capital Management Company, L.P.
15.63%
Foresite Capital Management, LLC
10.35%
Samsara BioCapital, LLC
4.96%
VenBio Partners LLC
4.77%
The Vanguard Group, Inc.
4.16%
Outro
60.14%
Tipos de investidores
Investidores
Proporção
Private Equity
34.07%
Investment Advisor
16.05%
Hedge Fund
12.54%
Investment Advisor/Hedge Fund
9.97%
Venture Capital
7.65%
Individual Investor
0.82%
Research Firm
0.78%
Bank and Trust
0.48%
Pension Fund
0.04%
Outro
17.59%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
192
79.50M
82.06%
+19.19M
2025Q2
152
55.51M
57.84%
+13.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Ayur Maya Capital Management Company, L.P.
15.14M
15.63%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
10.03M
10.35%
-5.17M
-34.02%
Jun 30, 2025
Samsara BioCapital, LLC
4.80M
4.96%
--
--
Jun 30, 2025
VenBio Partners LLC
4.62M
4.77%
+1.83M
+65.74%
Jun 30, 2025
The Vanguard Group, Inc.
3.40M
3.51%
+2.47M
+263.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.81M
3.93%
+2.46M
+182.05%
Jun 30, 2025
Trium Capital LLP
2.65M
2.73%
+2.65M
--
Jun 30, 2025
Nextech Invest, Ltd.
2.92M
3.01%
+1.44M
+97.43%
Jun 30, 2025
Cormorant Asset Management, LP
2.15M
2.22%
--
--
Jun 30, 2025
Tang Capital Management, LLC
2.00M
2.06%
+2.00M
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Ver Mais
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
iShares Micro-Cap ETF
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.03%
iShares Russell 2000 Value ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
